Anavex Life Sciences Corp. Publishes Oral Blarcamesine Presentation Reporting 36.3% Slowing in Early Alzheimer’s Decline

Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

AVXL

0.00
  • Anavex published a medical research presentation on oral blarcamesine in early Alzheimer’s disease, focusing on convenience for patients and caregivers and long-term time saved.
  • The document describes the ATTENTION-AD Phase IIb/III program, including a 48-week randomized, double-blind, placebo-controlled trial followed by an open-label extension with combined follow-up of up to 192 weeks.
  • In the Phase IIb/III trial, the presentation reports a 36.3% slowing of clinical progression at week 48 on the ADAS-Cog13 endpoint versus placebo.
  • It also reports 77.4 weeks of time saved versus an ADNI matched control group after 144 weeks of treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.